Recently we published Ph 1 results in healthy volunteers of our defined bacterial consortium VE303 that informed rational dose selection. Today, at #DDW22, we present data showing that VE303 is efficacious in Ph 2 and that higher dose ➡️ better colonization ➡️ higher activity

Last day at #DDW2022! Had a great time this morning sharing our work to understand why the VE303 higher dose elicits a better clinical response in C. difficile patients.

An exciting day at Vedanta with the launching of our large-scale manufacturing facility! We're ready to make lots and lots of bug-drugs.

We published in JAMA the results of a randomized Phase 2 study of @vedantabio‘s lead candidate VE303 for prevention of recurrent C. difficile infection (rCDI) 👉🧵/1